

Partnering for patient-centric, sustainable health care

Value-based agreements as enablers for innovative care delivery

Laurent Storme - Associate Director - MedTech Commercial Boston Consulting Group

2nd Value-Based Procurement Conference



Value-Based Agreements formalize buyer-seller collaboration linked to outcomes

What is Value-Based Agreement (VBA)?

VBA implements an agreement linking value transfer (payment or reimbursement) of a technology or solution to the real-world outcomes or other benefits it provides when used by physicians/nurses or patients in practice

Medical technology or solution Medtech Agreement Health Care Provider Value transfer (payment


or reimbursement)

How does VBA relate to value-based procurement (VBP)?

VBA formalizes a procurement process with the use of value criteria and evidence



of benefits






Risk/benefit sharing

Five key elements of Value-Based Agreements







Outcome measurement and monitoring



Target values or range for each criterion



Patient cohort(s)

definition
including
risk factors



Financial specifications

VBA taxonomy | five types of value-based agreements



Processbased care discount

Discounts and/or contractually agreed price paid based on achieving process compliance with evidence-based clinical intervention

Easy to implement and monitor



Product or service guarantee

Full or part of product cost returned if product usage fails (i.e., process/outcomes not achieved despite correct usage)

Cost due to not achieving benefit promised by supplier



Value sharing by product or service

Payment tied to larger cost/full provider cost beyond product price

Often broader outcomes/benefits contracted



Value sharing by alternative payment model

Hospital and supplier jointly partake in alternative payment program (e.g., bundle) share same upside/downside



Fully integrated care provision including value

Medtech company takes on full care provision with full upside and downside and reimbursement from payer

Less

More

Shared value included in the agreement/collaboration between supplier and buyer

Insights from Value-Based Agreement overview



Challenges to overcome



- Define clearly what you want to solve
- Get early buy in from all stakeholders
- Keep it simple, be reasonable and pragmatic
- Focus on succinct patient cohorts, with clear and easy way to measure criteria in daily practice
- Align provider/ supplier interests via VBA on few strong focus criteria
- Establish partnership that warrants time and resources investment on both sides

- Outcome measurement at contracting authority not in place (to capture baseline & improvement)
- Budget impact multi-year and potentially in different budgets that are currently siloed
- Legal mechanism and risks regarding court challenges still unclear
- Specifying outcome/ cost criteria and estimating impact/ setting targets difficult
- Medtech with limited experience and established contract models
- Objective monitoring (third party without interest in either direction) needed

Disclaimer

The services and materials provided by The Boston Consulting Group (BCG) are subject to BCG's Standard Terms (a copy of which is available upon request) or such other agreement as may have been previously executed by BCG. BCG does not provide legal, accounting, or tax advice. The Client is responsible for obtaining independent advice concerning these matters. This advice may affect the guidance given by BCG. Further, BCG has made no undertaking to update these materials after the date hereof, notwithstanding that such information may become outdated or inaccurate.

The materials contained in this presentation are designed for the sole use by the board of directors or senior management of the Client and solely for the limited purposes described in the presentation. The materials shall not be copied or given to any person or entity other than the Client ("Third Party") without the prior written consent of BCG. These materials serve only as the focus for discussion; they are incomplete without the accompanying oral commentary and may not be relied on as a stand-alone document. Further, Third Parties may not, and it is unreasonable for any Third Party to, rely on these materials for any purpose whatsoever. To the fullest extent permitted by law (and except to the extent otherwise agreed in a signed writing by BCG), BCG shall have no liability whatsoever to any Third Party, and any Third Party hereby waives any rights and claims it may have at any time against BCG with regard to the services, this presentation, or other materials, including the accuracy or completeness thereof. Receipt and review of this document shall be deemed agreement with and consideration for the foregoing.

BCG does not provide fairness opinions or valuations of market transactions, and these materials should not be relied on or construed as such. Further, the financial evaluations, projected market and financial information, and conclusions contained in these materials are based upon standard valuation methodologies, are not definitive forecasts, and are not guaranteed by BCG. BCG has used public and/or confidential data and assumptions provided to BCG by the Client. BCG has not independently verified the data and assumptions used in these analyses. Changes in the underlying data or operating assumptions will clearly impact the analyses and conclusions.